Cited by 286Antibiotic Resistance in BacteriaBacterial Genetics and BiotechnologyDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1

Open access

Dean, Charles R., Visalli, Melissa A., Projan, Steven J., Sum, Phaik-Eng, Bradford, Patricia A.·2003·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.47.3.972-978.2003PMC PMC149306

Open this paper in CoChat — free account

Abstract

Pseudomonas aeruginosa strains are less susceptible to tigecycline (previously GAR-936; MIC, 8 μg/ml) than many other bacteria (P. J. Petersen, N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa, Antimicrob. Agents Chemother. 43:738-744, 1999). To elucidate the mechanism of resistance to tigecycline, P. aeruginosa PAO1 strains defective in the MexAB-OprM and/or MexXY (OprM) efflux pumps were tested for susceptibility to tigecycline. Increased susceptibility to tigecycline (MIC, 0.5 to 1 μg/ml) was specifically associated with loss of MexXY. Transcription of mexX and mexY was also responsive to exposure of cells to tigecycline. To test for the emergence of compensatory efflux pumps in the absence of MexXY-OprM, mutants lacking MexXY-OprM were plated on medium containing tigecycline at 4 or 6 μg/ml. Resistant mutants were readily recovered, and these also had decreased susceptibility to several other antibiotics, suggesting efflux pump recruitment. One representative carbenicillin-resistant strain overexpressed OprM, the outer membrane channel component of the MexAB-OprM efflux pump. The mexAB-oprM repressor gene, mexR , from this strain contained a 15-bp in-frame deletion. Two representative chloramphenicol-resistant strains showed expression of an outer membrane protein slightly larger than OprM. The mexCD-OprJ repressor gene, nfxB , from these mutants contained a 327-bp in-frame deletion and an IS element insertion, respectively. Together, these data indicated drug efflux mediated by MexCD-OprJ. The MICs of the narrower-spectrum semisynthetic tetracyclines doxycycline and minocycline increased more substantially than did those of tigecycline and other glycylcyclines against the MexAB-OprM- and MexCD-OprJ-overexpressing mutant strains. This suggests that glycylcyclines, although they are subject to efflux from P. aeruginosa , are generally inferior substrates for P. aeruginosa efflux pumps than are narrower-spectrum tetracyclines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.47.3.972-978.2003

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
Stover, C. K., Pham, X. Q., Erwin, A. L., Mizoguchi, S., Warrener, P., Hickey, M. J., Brinkman, F. S. L., HUFNAGLE, W. O., Kowalik, D., Mj, L., et al. (2000) · Nature · doi:10.1038/35023079 · Cited by 4,544
Proton-dependent multidrug efflux systems
Paulsen, I. T., Brown, M. H., & Skurray, R. A. (1996) · Microbiological Reviews · doi:10.1128/mr.60.4.575-608.1996 · Cited by 1,089
Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa : Novel Agents for Combination Therapy
Lomovskaya, O., Warren, M. S., Lee, A. Y., Galazzo, J. L., Fronko, R. M., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.105-116.2001 · Cited by 903
Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa
Li, X. Z., Nikaido, H., & Poole, K. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.1948 · Cited by 660
Characterization of MexE–MexF–OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa
Köhler, T., Michéa-Hamzehpour, M., Henze, U. U., Gotoh, N., Curty, L. K., & Péchère, J.-C. (1997) · Molecular Microbiology · doi:10.1046/j.1365-2958.1997.2281594.x · Cited by 549
Overexpression of the mexC–mexD–oprJ efflux operon in nfxB‐type multidrug‐resistant strains of Pseudomonas aeruginosa
Poole, K., Gotoh, N., Tsujimoto, H., Zhao, Q., 和田明久, Yamasaki, T., Neshat, S., Yamagishi, J., Li, X.-Z., & Nishino, T. (1996) · Molecular Microbiology · doi:10.1046/j.1365-2958.1996.281397.x · Cited by 443
Cross-Resistance between Triclosan and Antibiotics in Pseudomonas aeruginosa Is Mediated by Multidrug Efflux Pumps: Exposure of a Susceptible Mutant Strain to Triclosan Selects nfxB Mutants Overexpressing MexCD-OprJ
Chuanchuen, R., Beinlich, K., Hoang, T. T., Becher, A., Karkhoff-Schweizer, R. R., & Schweizer, H. P. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.428-432.2001 · Cited by 427
In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9- t -Butylglycylamido Derivative of Minocycline (GAR-936)
Petersen, P. J., Jacobus, N. V., Weiss, W. J., Sum, P., & TESTA, R. T. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.738 · Cited by 413
Self-citation
Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of Escherichia coli
Fralick, J. A. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.19.5803-5805.1996 · Cited by 409

Show all 43 references

Sorted by citations

Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Antibacterial-Resistant Pseudomonas aeruginosa : Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
Lister, P., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,901
The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria
Li, X.-Z., Plésiat, P., & Nikaido, H. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00117-14 · Cited by 1,648
Multidrug-resistance efflux pumps ? not just for resistance
Piddock, L. J. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1464 · Cited by 1,523
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K. P., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,389
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231
Efflux-mediated antimicrobial resistance
Poole, K. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki171 · Cited by 1,082
Antimicrobial Resistance and Virulence: a Successful or Deleterious Association in the Bacterial World?
Beceiro, A., Tomás, M., & Bou, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-12 · Cited by 1,118
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2009) · Drugs · doi:10.2165/11317030-000000000-00000 · Cited by 1,017
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 803
Tetracycline Antibiotics and ResistancePreprint
Grossman, T. H. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025387 · Cited by 737
Intrinsic antibiotic resistance: Mechanisms, origins, challenges and solutions
Cox, G., & Wright, G. D. (2013) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2013.02.009 · Cited by 788
The role of antibiotics and antibiotic resistance in nature
Aminov, R. I. (2009) · Environmental Microbiology · doi:10.1111/j.1462-2920.2009.01972.x · Cited by 720
Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review
Pachori, P., Gothalwal, R., & Gandhi, P. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.04.001 · Cited by 636
Efflux-mediated multiresistance in Gram-negative bacteria
Poole, K. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2004.00763.x · Cited by 612
Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium
Mesaros, N. E., Nordmann, P., Plésiat, P., Roussel‐Delvallez, M., Eldere, J. V., Glupczynski, Y., Laethem, Y. V., Jacobs, F., Lebecque, P., Malfroot, A., et al. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01681.x · Cited by 585
Bacterial resistance to antibiotics: Active efflux and reduced uptake
Kumar, A., & Schweizer, H. P. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.004 · Cited by 569
Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance.
Blair, J. M., Richmond, G. E., & Piddock, L. J. (2014) · Future Microbiology · doi:10.2217/fmb.14.66 · Cited by 481
Aminoglycoside Resistance in Pseudomonas aeruginosa
Poole, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.479-487.2005 · Cited by 469
Modes and Modulations of Antibiotic Resistance Gene Expression
Depardieu, F., Podglajen, I., Leclercq, R., Collatz, E., & Courvalin, P. M. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00015-06 · Cited by 424
Mechanisms of antibiotic resistance
Munita, J. M., & Arias, C. A. (2016) · Virulence Mechanisms of Bacterial Pathogens · doi:10.1128/9781555819286.ch17 · Cited by 421
Benzalkonium Chlorides: Uses, Regulatory Status, and Microbial Resistance
Pereira, B. M. P., & Tagkopoulos, I. (2019) · Applied and Environmental Microbiology · doi:10.1128/aem.00377-19 · Cited by 424
Overexpression of Resistance-Nodulation-Cell Division Pump AdeFGH Confers Multidrug Resistance in Acinetobacter baumannii
Coyne, S., Rosenfeld, N., Lambert, T., Courvalin, P. M., & Périchon, B. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00155-10 · Cited by 365
Responses of Pseudomonas aeruginosa to antimicrobials
Morita, Y., Tomida, J., & Kawamura, Y. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00422 · Cited by 345
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†
Hawkey, P. M., Warren, R. E., Livermore, D. M., McNulty, C. A. M., Enoch, D., Otter, J. A., & Wilson, A. P. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky027 · Cited by 331
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
Yaghoubi, S., Zekiy, A. O., Krůtová, M., Gholami, M., Kouhsari, E., Sholeh, M., Ghafouri, Z., & Maleki, F. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-04121-1 · Cited by 332
Mechanisms of drug efflux and strategies to combat them: Challenging the efflux pump of Gram-negative bacteria
Pagès, J., & Amaral, L. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.12.011 · Cited by 328
Antibiotic resistance in aquaculture and aquatic organisms: a review of current nanotechnology applications for sustainable management
Okeke, E. S., Chukwudozie, K. I., Nyaruaba, R., Ita, R. E., Oladipo, A., Ejeromedoghene, O., Atakpa, E. O., Agu, C. V., & Okoye, C. O. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22319-y · Cited by 343
Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options
Cerceo, E. A., Deitelzweig, S. B., Sherman, B. M., & Amin, A. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2015.0220 · Cited by 313
Multi-targeting by monotherapeutic antibacterials
Silver, L. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2202 · Cited by 311
Multidrug-resistantPseudomonas aeruginosaandAcinetobacter baumannii: resistance mechanisms and implications for therapy
Zavascki, A. P., Carvalhaes, C. G., Picão, R. C., & Gales, A. C. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.108 · Cited by 322
Tigecycline
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 299
Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae
Lv, L., Wan, M., Wang, C.-Z., Gao, X., Yang, Q., Partridge, S. R., Wang, Y., Zong, Z., Doi, Y., Shen, J., et al. (2020) · mBio · doi:10.1128/mbio.02930-19 · Cited by 293
Multidrug-Resistant Gram-Negative Infections
Giamarellou, H., & Poulakou, G. (2009) · Drugs · doi:10.2165/11315690-000000000-00000 · Cited by 286
Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature
Bender, J. K., Cattoir, V., Hegstad, K., Sadowy, E., Coque, T. M., Westh, H., Hammerum, A. M., Schaffer, K., Burns, K., Murchan, S., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.002 · Cited by 297
Tigecycline: what is it, and where should it be used?
Livermore, D. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki291 · Cited by 261
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii
Peleg, A. Y., Adams, J. M., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01198-06 · Cited by 257
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report
Peleg, A. Y., Potoski, B. A., Rea, R. S., Adams, J. M., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., & Paterson, D. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl441 · Cited by 248
AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complex
Ruzin, A. V., Keeney, D. R., & Bradford, P. A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm058 · Cited by 238
Self-citation
Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
Kakoullis, L., Papachristodoulou, E., Chra, P., & Panos, G. Z. (2021) · Antibiotics · doi:10.3390/antibiotics10040415 · Cited by 269
A Novel MATE Family Efflux Pump Contributes to the Reduced Susceptibility of Laboratory-Derived Staphylococcus aureus Mutants to Tigecycline
McAleese, F., Petersen, P. J., Ruzin, A. V., Dunman, P. M., Murphy, E., Projan, S. J., & Bradford, P. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1865-1871.2005 · Cited by 233
Self-citation
The Antibiotic Resistome: A Guide for the Discovery of Natural Products as Antimicrobial Agents
Hobson, C., Chan, A. N., & Wright, G. D. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01214 · Cited by 229
Tigecycline: A New Glycylcycline for Treatment of Serious Infections
Noskin, G. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431672 · Cited by 224
The Development of Third-Generation Tetracycline Antibiotics and New Perspectives
Rusu, A., & Buta, L. E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122085 · Cited by 228
Functional, biophysical, and structural bases for antibacterial activity of tigecycline
Olson, M. W., Ruzin, A., Feyfant, E., Rush, T. S., O'Connell, J., & Bradford, P. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01499-05 · Cited by 207
Self-citation
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)
Hoban, D. J., Bouchillon, S. K., Johnson, B., Johnson, J. L., & Dowzicky, M. J. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.06.001 · Cited by 201
Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae
Ruzin, A. V., Visalli, M. A., Keeney, D. R., & Bradford, P. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1017-1022.2005 · Cited by 205
Self-citation
MexXY multidrug efflux system of Pseudomonas aeruginosa
Morita, Y., Tomida, J., & Kawamura, Y. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00408 · Cited by 197
Tigecycline: First of a New Class of Antimicrobial Agents
Rose, W. E., & Rybak, M. J. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.8.1099 · Cited by 196
Tetracycline-inactivating enzymes from environmental, human commensal, and pathogenic bacteria cause broad-spectrum tetracycline resistance
Gasparrini, A. J., Markley, J. L., Kumar, H., Wang, B., Fang, L., Irum, S., Symister, C. T., Wallace, M. A., Burnham, C. D., Andleeb, S., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0966-5 · Cited by 204
Interaction of antibacterial compounds with RND eﬄux pumps in Pseudomonas aeruginosa
Dreier, J., & Ruggerone, P. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00660 · Cited by 202
Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline
Reinert, R. R., Low, D. E., Rossi, F. P. N., Zhang, X., Wattal, C., & Dowzicky, M. J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm310 · Cited by 189
The nature and epidemiology of OqxAB, a multidrug efflux pump
Li, J., Zhang, H., Ning, J., Sajid, A., Cheng, G., Yuan, Z., & Hao, H. (2019) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-019-0489-3 · Cited by 188
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies
Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., & Falagas, M. E. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn311 · Cited by 184
Tigecycline: an update
Stein, G. E., & Babinchak, T. (2013) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.12.004 · Cited by 183
The emergence of clinical resistance to tigecycline
Sun, Y., Cai, Y., Liu, X., Bai, N., Liang, B., & Wang, R. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.09.005 · Cited by 182
Effect of subinhibitory concentrations of benzalkonium chloride on the competitiveness of Pseudomonas aeruginosa grown in continuous culture
Cay, P. H. M., Ocampo-Sosa, A. A., & Fleming, G. T. A. (2009) · Microbiology · doi:10.1099/mic.0.029751-0 · Cited by 179
Challenges in Identifying New Antimicrobial Agents Effective for Treating Infections with Acinetobacter baumannii and Pseudomonas aeruginosa
Rice, L. B. (2006) · Clinical Infectious Diseases · doi:10.1086/504487 · Cited by 175
Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case-control study
Matthaiou, D. K., Michalopoulos, A. S., Rafailidis, P. I., Karageorgopoulos, D. E., Papaioannou, V., Ntani, G., Samonis, G., & Falagas, M. E. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181652fae · Cited by 164
MexAB‐OprM hyperexpression in NalC‐type multidrug‐resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720‐PA3719
Cao, L., Srikumar, R., & Poole, K. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04210.x · Cited by 160
Pseudomonas aeruginosa reference strains PAO1 and PA14: A genomic, phenotypic, and therapeutic review
Grace, A., Sahu, R., Owen, D. R., & Dennis, V. A. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1023523 · Cited by 156
MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli
Keeney, D. R., Ruzin, A. V., McAleese, F., Murphy, E., & Bradford, P. A. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm397 · Cited by 155
Self-citation
Tigecycline: A glycylcycline antimicrobial agent
Doan, T.-L., Fung, H. B., Mehta, D., & Riska, P. F. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.08.011 · Cited by 152
Bacterial Efflux Pumps Involved in Multidrug Resistance and their Inhibitors: Rejuvinating the Antimicrobial Chemotherapy
Bhardwaj, A. K., & Mohanty, P. (2012) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489112799829710 · Cited by 148
Phenotypic and Genome-Wide Analysis of an Antibiotic-Resistant Small Colony Variant (SCV) of Pseudomonas aeruginosa
Wei, Q., Tarighi, S., Dötsch, A., Häußler, S., Müsken, M., Wright, V. J., Cámara, M., Williams, P. M., Haenen, S., Boerjan, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029276 · Cited by 133
Colistin and tigecycline resistance in carbapenemase-producing Gram-negative bacteria: emerging resistance mechanisms and detection methods
Sekyere, J. O., Govinden, U., Bester, L. A., & Essack, S. Y. (2016) · Journal of Applied Microbiology · doi:10.1111/jam.13169 · Cited by 134
Resistance and Virulence of Pseudomonas aeruginosa Clinical Strains Overproducing the MexCD-OprJ Efflux Pump
Jeannot, K., Elsen, S., Köhler, T., Attrée, I., van Delden, C., & Plésiat, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01107-07 · Cited by 134
mexEF-oprN Multidrug Efflux Operon of Pseudomonas aeruginosa : Regulation by the MexT Activator in Response to Nitrosative Stress and Chloramphenicol
Fetar, H., Gilmour, C., Klinoski, R., Daigle, D. M., Dean, C. R., & Poole, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00830-10 · Cited by 134
Self-citation
In Vitro Activity of Tigecycline against Isolates from Patients Enrolled in Phase 3 Clinical Trials of Treatment for Complicated Skin and Skin‐Structure Infections and Complicated Intra‐Abdominal Infections
Bradford, P. A., Weaver‐Sands, D. T., & Petersen, P. J. (2005) · Clinical Infectious Diseases · doi:10.1086/431673 · Cited by 133
Self-citation
Tigecycline resistance in clinical isolates of Enterococcus faecium is mediated by an upregulation of plasmid-encoded tetracycline determinants tet (L) and tet (M)
Fiedler, S., Bender, J. K., Klare, I., Halbedel, S., Grohmann, E., Szewzyk, U., & Werner, G. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv420 · Cited by 130
Taking inventory: antibacterial agents currently at or beyond Phase 1
Bush, K., Macielag, M. J., & Weidner‐Wells, M. A. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.013 · Cited by 126
Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies
Entenza, J. M., & Moreillon, P. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.11.006 · Cited by 122
Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936)
Hirata, T., Saito, A., Nishino, K., Tamura, N., & Yamaguchi, A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2179-2184.2004 · Cited by 122
ramR Mutations in Clinical Isolates of Klebsiella pneumoniae with Reduced Susceptibility to Tigecycline
Hentschke, M., Wolters, M., Sobottka, I., Rohde, H., & Aepfelbacher, M. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00085-10 · Cited by 117
Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline)
Zuckerman, J. M., Qamar, F., & Bono, B. R. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.03.012 · Cited by 116
Multiple Mutations Lead to MexXY-OprM-Dependent Aminoglycoside Resistance in Clinical Strains of Pseudomonas aeruginosa
Guénard, S., Muller, C., Monlezun, L., Bénas, P., Broutin, I., Jeannot, K., & Plésiat, P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01252-13 · Cited by 115
RamA, a Transcriptional Regulator, and AcrAB, an RND-Type Efflux Pump, are Associated with Decreased Susceptibility to Tigecycline in Enterobacter cloacae
Keeney, D. R., Ruzin, A. V., & Bradford, P. A. (2007) · Microbial Drug Resistance · doi:10.1089/mdr.2006.9990 · Cited by 111
Self-citation
Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance
Wolter, D. J. (2004) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2004.05.039 · Cited by 104
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae
Vasilev, K. A., Reshedko, G., Orăsan, R., Sánchez, M., Teras, J., Babinchak, T., Dukart, G., Cooper, A., Dartois, N., Gandjini, H., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn249 · Cited by 102
Differential Impact of MexB Mutations on Substrate Selectivity of the MexAB-OprM Multidrug Efflux Pump of Pseudomonas aeruginosa
Middlemiss, J. K., & Poole, K. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.5.1258-1269.2004 · Cited by 99
Mutation of nfxB Causes Global Changes in the Physiology and Metabolism of Pseudomonas aeruginosa
Stickland, H. G., Davenport, P. W., Lilley, K. S., Griffin, J. L., & Welch, M. (2010) · Journal of Proteome Research · doi:10.1021/pr9011415 · Cited by 98
Insertional inactivation ofoprD in clinical isolates ofPseudomonas aeruginosaleading to carbapenem resistance
Wolter, D. J., Hanson, N. D., & Lister, P. (2004) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2004.tb09639.x · Cited by 97
Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds
Jadimurthy, R., Mayegowda, S. B., Nayak, S. C., Mohan, C. D., & Rangappa, K. S. (2022) · Biotechnology Reports · doi:10.1016/j.btre.2022.e00728 · Cited by 103
Tigecycline: a novel glycylcycline antibiotic
Zhanel, G. G., Karlowsky, J. A., Rubinstein, E., & Hoban, D. J. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.1.9 · Cited by 96
AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganii
Ruzin, A. V., Keeney, D. R., & Bradford, P. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.791-793.2005 · Cited by 93
Self-citation
Mechanisms and fitness costs of tigecycline resistance in Escherichia coli
Linkevičius, M., Sandegren, L., & Andersson, D. I. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt263 · Cited by 92
Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance
Pournaras, S., Koumaki, V., Spanakis, N., Gennimata, V., & Tsakris, A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.017 · Cited by 91
In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)
Bouchillon, S. K., Hoban, D. J., Johnson, B., Johnson, J. L., Hsiung, A., & Dowzicky, M. J. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.06.004 · Cited by 87
Amphiphilic Tobramycin–Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline
Lyu, Y., Yang, X., Goswami, S., Gorityala, B. K., Idowu, T., Domalaon, R., Zhanel, G. G., Shan, A., & Schweizer, F. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01742 · Cited by 86
Tigecycline: A new glycylcycline antimicrobial agent
Kasbekar, N. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050487 · Cited by 86
Staphylococci
Casey, A. L., Lambert, P. A., & Elliott, T. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(07)72175-1 · Cited by 87
Non-fermentative Gram-negative bacteria
Enoch, D., Birkett, C. I., & LUDLAM, H. A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(07)72176-3 · Cited by 83
Drug Treatment for Multidrug-Resistant Acinetobacter Baumannii Infections
Bassetti, M., Righi, E., Esposito, S., Petrosillo, N., & Nicolini, L. A. (2008) · Future Microbiology · doi:10.2217/17460913.3.6.649 · Cited by 82
Adaptive resistance to cationic compounds in Pseudomonas aeruginosa
Skiada, A., Markogiannakis, A., Plachouras, D., & Daikos, G. L. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.11.019 · Cited by 80
Tigecycline
Rubinstein, E., & Vaughan, D. (2005) · Drugs · doi:10.2165/00003495-200565100-00002 · Cited by 78
Pharmacokinetic and pharmacodynamic evaluation of tigecycline
Giamarellou, H., & Poulakou, G. (2011) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.623126 · Cited by 78
Macrolides, Ketolides, and Glycylcyclines: Azithromycin, Clarithromycin, Telithromycin, Tigecycline
Zuckerman, J. M., Qamar, F., & Bono, B. R. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.06.013 · Cited by 75
Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs
Shen, F., Han, Q., Xie, D., Fang, M., Zeng, H., & Deng, Y. (2015) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2015.08.009 · Cited by 74
Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates
Fritsche, T. R., Strabala, P., Sader, H. S., Dowzicky, M. J., & Jones, R. N. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.06.010 · Cited by 73
Characterizing the Mechanism of Action of an Ancient Antimicrobial, Manuka Honey, against Pseudomonas aeruginosa Using Modern Transcriptomics
Bouzo, D., Cokcetin, N. N., Li, L., Ballerin, G., Bottomley, A. L., Lazenby, J., Whitchurch, C. B., Paulsen, I. T., Hassan, K. A., & Harry, E. J. (2020) · mSystems · doi:10.1128/msystems.00106-20 · Cited by 73

Authors: Dean, C. R., Visalli, M. A., Projan, S. J., Sum, P.-E., & Bradford, P. A.
Affiliations: Wyeth (US)
Corresponding author: Dean, Charles R.
ORCID: Dean, Charles R.
Bradford, Patricia A.
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2003-03
Volume: 47
Issue: 3
Pages: 972-978
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.47.3.972-978.2003
PMC: PMC149306
OpenAlex: W2139818499
Cited by: 286
References: 43
Citations by year: 2026: 8 · 2025: 7 · 2024: 4 · 2023: 6 · 2022: 13 · 2021: 14 · 2020: 8 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 14 · 2015: 9 · 2014: 8 · 2013: 10 · 2012: 12
FWCI: 9.42
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: tigecycline resistance, Pseudomonas aeruginosa PAO1, efflux pumps, MexXY-OprM, MexCD-OprJ, MexAB-OprM, OprM, mexR, glycylcyclines, tetracycline, doxycycline, minocycline, carbenicillin resistance
MeSH terms: Tigecycline, Anti-Bacterial Agents, Bacterial Outer Membrane Proteins, Bacterial Proteins, Culture Media, DNA, Bacterial, Electrophoresis, Polyacrylamide Gel, Microbial Sensitivity Tests, Minocycline, Pseudomonas aeruginosa, Tetracycline Resistance, Tetracyclines, Transcription, Genetic, Blotting, Western, Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks